Biotech Analysts, along with Dr. Gary Steinberg, Professor of the Urology Dept at Rush University Medical Center, discuss emerging therapeutics in non-muscle-invasive bladder cancer (NMIBC), (relevant companies CGON and JNJ) on an Analyst/Industry conference call to be held on May 6 at 1 pm. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- 3 Best Stocks to Buy Now, 5/6/2024, According to Top Analysts
- Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
- CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
- CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting